Last week, I had the opportunity to participate in a panel discussion at the Elsevier Business Intelligence FDA/CMS Summit entitled, “Beyond the Label.”
Most Recent Posts
When we launched Conversations in June of this year, our goal was to blend formal contributors with an ongoing opportunity for experts and thought leaders to weigh in on a broad range of high-level policy topics. The forum has been a tremendous success.
Worth a read are the commentaries surrounding the latest Room for Debate question posed by the New York Times; it’s a good snapshot into the various views on the issue of biopharmaceutical and physician interaction.
PhRMA Pushes Back on New York Times
Discovering and developing new treatments for the world’s most pressing health challenges helps inspire the work of innovators across the biopharmaceutical sector. More importantly, it’s our end-goal to ensure that patients around the world can obtain such innovative treatments in a timely manner.
It’s hard to see the silver lining when it comes to cancer, as many view the disease as a devastating prognosis. And while cancer can take a serious toll on patients and their loved ones, they should know that tremendous strides are being made in the research and development of new cancer medicines that are allowing patients to lead longer, healthier lives.
I walked away from Friday morning’s “Research in Your Backyard: Pharmaceutical Clinical Trials in Minnesota” breakfast meeting in Minneapolis mightily impressed with two things: Frank Jaskulke’s very maroon and gold running shoes –a great contrast with the conservative suit the Minnesota life sciences thought leader was wearing – and
Recently the 26th Anniversary of World AIDS Day was celebrated, along with the remarkable progress that has been made against this disease.
Between Lake Champlain and the Green Mountains of Vermont, the Burlington area houses one of the economic cores of the region. Yesterday’s "Research in Your Backyard," event brought together researchers, doctors and patients, and focused on the biopharmaceutical industry’s contributions to the state’s prosperity through